SGMO (Sangamo Therapeutics) Float Percentage Of Total Shares Outstanding : 97.53% (As of May. 06, 2025)

View and export this data going back to 2000. Start your Free Trial

What is Sangamo Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Sangamo Therapeutics's float shares is 223.52 Mil. Sangamo Therapeutics's total shares outstanding is 229.19 Mil. Sangamo Therapeutics's float percentage of total shares outstanding is 97.53%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Sangamo Therapeutics's Insider Ownership is 3.84%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Sangamo Therapeutics's Institutional Ownership is 27.44%.

Sangamo Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Sangamo Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	223.52	/	229.19
	=	97.53%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sangamo Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sangamo Therapeutics Inc (NAS:SGMO) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

0R1D:UK GBY:Germany GBY:Germany

Address

501 Canal Boulevard, Richmond, CA, USA, 94804

Website

https://www.sangamo.com

Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

Executives

Biogen Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142
Beers Courtney	director	C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BOULEVARD, BRISBANE CA 94005
Margaret A Horn	director	925 PAGE MILL ROAD, PALO ALTO CA 94304
Nathalie Dubois-stringfellow	officer: SVP-Chief Development Officer	C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BOULEVARD, BRISBANE CA 94005
John Markels	director	C/O SANGAMO THERAPEUTICS, INC., POINT RICHMOND TECH CTR, 501 CANAL BLVD., RICHMOND CA 94804
H Stewart Parker	director
Biogen Ma Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142
Scott B. Willoughby	officer: SVP, Gen. Counsel & Secretary	7000 MARINA BLVD, BRISBANE CA 94005
Gary Loeb	officer: EVP & General Counsel	5885 HOLLIS ST., SUITE 100, EMERYVILLE CA 94608
Jason D. Fontenot	officer: SVP, Chief Scientific Officer	7000 MARINA BLVD, BRISBANE CA 94005
Robert J. Schott	officer: SVP, Head of Development	7000 MARINA BLVD, BRISBANE CA 94005
Rolf Andrew Ramelmeier	officer: EVP, Technical Operations	7000 MARINA BLVD, BRISBANE CA 94005
Saira Ramasastry	director	501 CANAL BLVD., RICHMOND CA 94804
Kenneth J. Hillan	director	C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
David Mark Mcclung	officer: EVP Chief Business Officer	7000 MARINA BLVD, BRISBANE CA 94005